The World Health Organization (WHO) has updated its patient care guidelines to include interleukin-6 receptor blockers, a class of medicines that are lifesaving in patients who are severely or critically ill with COVID-19, especially when administered alongside corticosteroids.
These were the findings from a prospective and a living network meta-analysis initiated by WHO, the largest such analysis on the drugs to date.
Data from over 10 000 patients enrolled in 27 clinical trials were considered. These are the first drugs found to be effective against COVID-19 since corticosteroids were recommended by WHO in September 2020.